Study #2022-0298
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine
Description
The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed/Refractory Follicular Lymphoma
Study phase:
Phase III
Physician name:
Sairah Ahmed
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-855-319-9556
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.